image
Healthcare - Biotechnology - NASDAQ - US
$ 86.65
0.51 %
$ 4.37 B
Market Cap
-18.28
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SLNO stock under the worst case scenario is HIDDEN Compared to the current market price of 86.7 USD, Soleno Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SLNO stock under the base case scenario is HIDDEN Compared to the current market price of 86.7 USD, Soleno Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SLNO stock under the best case scenario is HIDDEN Compared to the current market price of 86.7 USD, Soleno Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SLNO

image
$90.0$90.0$85.0$85.0$80.0$80.0$75.0$75.0$70.0$70.0$65.0$65.0$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
-184 M OPERATING INCOME
-345.65%
-176 M NET INCOME
-351.04%
-69.1 M OPERATING CASH FLOW
-177.05%
-226 M INVESTING CASH FLOW
0.00%
213 M FINANCING CASH FLOW
18.33%
0 REVENUE
0.00%
0 OPERATING INCOME
100.00%
-43.8 M NET INCOME
21.81%
-32.8 M OPERATING CASH FLOW
-36.52%
22.9 M INVESTING CASH FLOW
256.00%
3.22 M FINANCING CASH FLOW
-94.36%
Balance Sheet Soleno Therapeutics, Inc.
image
Current Assets 294 M
Cash & Short-Term Investments 291 M
Receivables 0
Other Current Assets 2.45 M
Non-Current Assets 37.1 M
Long-Term Investments 27.2 M
PP&E 2.98 M
Other Non-Current Assets 6.89 M
88.05 %8.22 %Total Assets$331.0m
Current Liabilities 18.7 M
Accounts Payable 8.88 M
Short-Term Debt 526 K
Other Current Liabilities 9.34 M
Non-Current Liabilities 67.1 M
Long-Term Debt 52.3 M
Other Non-Current Liabilities 14.8 M
10.34 %10.88 %60.91 %17.25 %Total Liabilities$85.9m
EFFICIENCY
Earnings Waterfall Soleno Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 188 M
Operating Income -184 M
Other Expenses -8.58 M
Net Income -176 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)(200m)(200m)000(188m)(184m)9m(176m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-71.74% ROE
-71.74%
-53.13% ROA
-53.13%
-58.97% ROIC
-58.97%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Soleno Therapeutics, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -176 M
Depreciation & Amortization 1.99 M
Capital Expenditures -218 K
Stock-Based Compensation 100 M
Change in Working Capital 6.02 M
Others -863 K
Free Cash Flow -69.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Soleno Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for SLNO of $79.4 , with forecasts ranging from a low of $59 to a high of $105 .
SLNO Lowest Price Target Wall Street Target
59 USD -31.91%
SLNO Average Price Target Wall Street Target
79.4 USD -8.33%
SLNO Highest Price Target Wall Street Target
105 USD 21.18%
Price
Max Price Target
Min Price Target
Average Price Target
110110100100909080807070606050504040Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Soleno Therapeutics, Inc.
image
Sold
0-3 MONTHS
339 K USD 1
3-6 MONTHS
201 M USD 8
6-9 MONTHS
868 K USD 4
9-12 MONTHS
66.9 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research, and the International Prader-Willi Syndrome Organisation Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research, and the International Prader-Willi Syndrome Organisation globenewswire.com - 2 weeks ago
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DCCR) for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA). globenewswire.com - 1 month ago
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome REDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced data presented from its clinical development program of VYKAT™ XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, at the Pediatric Endocrine Society (PES) Annual Meeting 2025, which was held May 15-18 in National Harbor, Maryland, USA. The presentation showed that resumption of VYKAT XR treatment in participants with PWS following a 16-week randomized withdrawal was associated with significant improvements in both hyperphagia and behavioral symptoms. globenewswire.com - 1 month ago
Soleno Therapeutics, Inc. (SLNO) Q1 2025 Earnings Call Transcript Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Anish Bhatnagar - Chief Executive Officer Meredith Manning - Chief Commercial Officer Jim Mackaness - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Debjit Chattopadhyay - Guggenheim Securities Kristen Kluska - Cantor Leland Gershell - Oppenheimer Brian Skorney - Baird James Condulis - Stifel Myriam Belghiti - LifeSci Capital Yale Jen - Laidlaw Operator Greetings, and welcome to the Soleno Therapeutics First Quarter 2025 Earnings Conference Call. At this time, note that all participants are in a listen-only mode. seekingalpha.com - 1 month ago
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the first quarter ended March 31, 2025. globenewswire.com - 1 month ago
Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. zacks.com - 2 months ago
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. globenewswire.com - 2 months ago
Soleno Therapeutics Announces VYKAT(TM) XR Launch REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR (diazoxide choline) extended-release tablets, the company's treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), which was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025. globenewswire.com - 2 months ago
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients. zacks.com - 3 months ago
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder The U.S. Food and Drug Administration (FDA) on Wednesday approved Soleno Therapeutics, Inc.'s SLNO Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). benzinga.com - 3 months ago
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th , at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). globenewswire.com - 3 months ago
Soleno Therapeutics to Participate in Upcoming February Investor Conferences REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February: globenewswire.com - 5 months ago
8. Profile Summary

Soleno Therapeutics, Inc. SLNO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 4.37 B
Dividend Yield 0.00%
Description Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Contact 203 Redwood Shores Parkway, Redwood City, CA, 94065 https://soleno.life
IPO Date Nov. 13, 2014
Employees 115
Officers Dr. Anish Bhatnagar M.D. Chairman, President, Chief Executive Officer & Chief Operating Officer Dr. Neil M. Cowen M.B.A., Ph.D. Senior Vice President of Drug Development Dr. Michael Huang M.D. Senior Vice President of Clinical Development Ms. Patricia C. Hirano M.P.H. Senior Vice President of Regulatory Affairs Dr. Mitchell Nagao M.B.A., Pharm.D. Senior Vice President of Medical Affairs Ms. Kristen Yen M.S. Senior Vice President of Global Clinical Operations and Patient Advocacy Ms. Meredith Manning M.B.A. Chief Commercial Officer Ms. Lauren Budesheim Vice President of People Mr. James H. MacKaness Chief Financial Officer & Compliance Officer Mr. Jesse Schumaker General Counsel